SR ONE CAPITAL MANAGEMENT, LLC has bought stock on 6 days since Feb 2022
10% owner at ADARx Pharmaceuticals, Inc., and 5 other companies
SEC CIK 0001853723 · Filings on SEC.gov ↗
SR ONE CAPITAL MANAGEMENT, LLC's record
3 months after each buy, from the first price a copier could get.
5 buys since 2022 with 3 months of prices.
Companies
Every filing
8 filings since Feb 2022, newest first
ADARx Pharmaceuticals, Inc.
10% owner
Odyssey Therapeutics, Inc.
10% owner
Avalyn Pharma Inc.
10% owner
Zenas Biopharma, Inc.
10% owner
Zenas Biopharma, Inc.
10% owner
Effector Therapeutics, Inc.
10% owner
Arcellx, Inc.
10% owner
Arcellx, Inc.
10% owner
About SR ONE CAPITAL MANAGEMENT, LLC
SR One Capital Management, LLC is a transatlantic biotechnology venture capital firm founded in 2020, specializing in partnering with founders and entrepreneurs to translate innovative science into medicines through a 'back-and-build' investment approach.( Headquartered with offices in key biotech hubs including Wayne (as per filings), Redwood City on the US West Coast, and London, UK, the firm focuses on companies with strong fundamentals, clear development pathways, and novel disease treatments, providing strategic support via its geographic reach.(
As of June 30, 2025, SR One manages approximately $461 million in discretionary assets across 17 clients, with top holdings including Arcellx Inc (33.49%), ARS Pharmaceuticals (15.18%), CRISPR Therapeutics (11.06%), and Zenas BioPharma, Inc. (ZBIO) at 10.32% of its portfolio, positioning it as a 10% owner and active corporate insider in recent trades.( Leadership includes partners like Jake Nunn in Redwood City and venture partners such as Eliot Charles in London, supported by roles in finance, legal, and compliance; the firm has raised multiple funds since inception, with 3 funds currently in market and 6 closed.(
Written by Perplexity from public sources.
Filings come from SEC EDGAR. Not investment advice.